Halozyme adds James Daly to board of directors
Halozyme Therapeutics disclosed the September 28, 2026 election in an 8-K filed with the SEC.
Halozyme Therapeutics, Inc. said in a Form 8-K that James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. on September 28, 2026.1
The filing said Daly's term will run until the company's 2029 annual meeting of stockholders, and he was not placed on any board committee at the time of his election.1
On compensation, Halozyme said Daly will be paid according to the company's standard non-employee director program, which currently includes cash retainers for board and committee service along with restricted stock and stock option grants, subject to any future revisions to that program.1 The company noted that the details of that director pay program were laid out in the proxy statement for the 2026 annual meeting, held on May 5, 2026, and that there are no arrangements tied to Daly's election and no related-party transactions between him and the company.1
The 8-K was signed on September 30, 2026 by Mark Snyder, Halozyme's Executive Vice President, Chief Legal Officer and Corporate Secretary.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.